Gilead to Test Remdesivir Delivered Through Inhalation

July 3, 2020

Gilead to Test Remdesivir Delivered Through Inhalation

Gilead will begin testing an inhaled version of their leading COVID-19 treatment, Remdesivir. It is currently administered to patients intravenously in a hospital setting, though delivery via a nebulizer is decidedly more patient-centric. Regardless of dosage form, Yourway has the means to transport, store, and ship even the most sensitive clinical trial samples globally.

Back to Index

Stay Connected

Want to stay informed about the latest news, updates, and opportunities at Yourway?

Join our newsletter mailing list to never miss an update!

Media

Upcoming Events

Precision in Pharma Supply Chain & Logistics Summit

November 17-18, 2025
Revere Hotel Boston Common

Schedule a Meeting

SCOPE Supply Chain & Logistics Leadership Summit

February 2-5, 2026
Orlando, Florida

Schedule a Meeting

Media

Articles

Mitigating Risk in Drug Development: The Strategic Role of Phase I Research Units

Open chat

Hello! How can I help you?